GlobeNewswire Inc.··ActgLong-Acting HIV Injectable Therapy Outperforms Daily Pills in Phase 3 Trial
Long-acting HIV injectable therapy significantly outperforms daily pills in Phase 3 trial, showing lower failure rates and improved outcomes for patients with adherence challenges.
JNJclinical triallong-acting injectable